Document Type : Original Article
Authors
1 MPH Department, Shiraz University of Medical Sciences, Shiraz, Iran
2 Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
3 Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
4 Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
Abstract
Background: Population aging and more prevalent westernized lifestyle would be expected to result in a markedly rising burden of colorectal cancer (CRC) in the future years. The aim of this study is to estimate the limited-time prevalence of CRC in Iran between 2015 and 2020. Materials and Methods: Aggregated CRC incidence data were extracted from the Iranian national cancer registry (IR.NCR) reports for 2003–2009 and from GLOBOCAN-2012 database for 2012. Incidence trends were analyzed by age groups, genders, histopathologic, and topographic subtypes to estimate annual percentage changes. Incidence was projected for 2020. The prevalence was estimated applying an adopted version of a previously introduced equation to estimate limited–time prevalence based on the incidence and survival data. Monte Carlo sensitivity analyses were applied to estimate 95% uncertainty levels (ULs). In each scenario, incidence, survival, annual percentage changes, and completeness of case ascertainment at IR.NCR were replaced under pre-assumed distributions. Results: Number of estimated within 1, 2-3 and 4-5-year CRC patients in 2015 were 13676 (95% UL: 10051–18807), 20964 (15835–28268), and 14485 (11188–19293), respectively. Estimated 5-year prevalence for 2020 (99463; 75150–134744) was 2.03 times of that for 2015. Highest 5-year prevalence was estimated in ages 55–59 for females and 75 + for males. Adenocarcinoma (41376; 31227 55898) was the most prevalent histologic subtype. The most prevalent tumor location was colon (30822, 23262–41638). Conclusion: A substantial growth in the prevalence of CRC survivors is highly expected for future years in Iran. Establishment of specialized institutes is highly recommended to provide medical and especially social supports for Iranian CRC survivors.
Keywords
1. |
Ghassemi H, Harrison G, Mohammad K. An accelerated nutrition transition in Iran. Public Health Nutr 2002;5:149-55. [PUBMED] |
2. | |
3. |
Pourmalek F, Abolhassani F, Naghavi M, Mohammad K, Majdzadeh R, Holakouie Naeini K, et al. Direct estimation of life expectancy in the Islamic Republic of Iran in 2003. East Mediterr Health J 2009;15:76-84. [PUBMED] |
4. |
Hassanzade J, Molavi E Vardanjani H, Farahmand M, Rajaiifard AR. Incidence and mortality rate of common gastrointestinal cancers in South of Iran, a population based study. Iran J Cancer Prev 2011;4:163-9. [PUBMED] |
5. |
Abdifard E, Ghaderi S, Hosseini S, Heidari M. Incidence trends of colorectal cancer in the West of Iran during 2000-2005. Asian Pac J Cancer Prev 2013;14:1807-11. [PUBMED] |
6. |
Najafi F, Mozaffari HR, Karami M, Izadi B, Tavvafzadeh R, Pasdar Y. Trends in incidence of gastrointestinal tract cancers in Western Iran, 1993-2007. Iran Red Crescent Med J 2011;13:805-10. [PUBMED] |
7. | |
8. |
Masoompour SM, Yarmohammadi H, Rezaianzadeh A, Lankarani KB. Cancer incidence in Southern Iran, 1998-2002: Results of population-based cancer registry. Cancer Epidemiol 2011;35:e42-7. [PUBMED] |
9. |
Vardanjani HM, Baneshi MR, Haghdoost A. Total and partial prevalence of cancer across Kerman Province, Iran, in 2014, using an Adapted Generalized Network Scale-up method. Asian Pac J Cancer Prev 2015;16:5493-8. [PUBMED] |
10. | |
11. |
Moradpour F, Fatemi Z. Estimation of the projections of the incidence rates, mortality and prevalence due to common cancer site in Isfahan, Iran. Asian Pac J Cancer Prev 2013;14:3581-5. [PUBMED] |
12. | |
13. | |
14. |
Marzban M, Haghdoost AA, Dortaj E, Bahrampour A, Zendehdel K. Completeness and underestimation of cancer mortality rate in Iran: A report from Fars Province in Southern Iran. Arch Iran Med 2015;18:160-6. [PUBMED] |
15. |
Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132:1133-45. [PUBMED] |
16. |
2012 G. Iran, Islamic Republic of (2012), Estimated Incidence and Prevalence, Adult Population: Both Sexes. France: IARC; 2013. Available from: http://www.globocan.iarc.fr/old/summary_table_pop_prev.asp?selection=91364&title=Iran%2C+Islamic+Republic+of&sex=0&window=1&sort=0&submit=%C2%A0Execute. [Last. [Last cited on 2016 Feb 14]. |
17. |
Bowel Cancer Survival Statistics: Cancer Research UK; 2014. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/survival. [Last cited on 2016 Mar 21]. |
18. |
Gelband H, Sankaranarayanan R, Gauvreau CL, Horton S, Anderson BO, Bray F, et al. Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: Key messages from Disease Control Priorities, 3rd edition. Lancet 2016;387:2133-44. [PUBMED] |
19. | |
20. |
Moradi A, Khayamzadeh M, Guya M, Mirzaei HR, Salmanian R, Rakhsha A, et al. Survival of colorectal cancer in Iran. Asian Pac J Cancer Prev 2009;10:583-6. [PUBMED] |
21. | |
22. |
Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97:72-81. [PUBMED] |
23. |
Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012;62:243-74. [PUBMED] |
24. |
Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S, et al. Fear of cancer recurrence in adult cancer survivors: A systematic review of quantitative studies. J Cancer Surviv 2013;7:300-22. [PUBMED] |
25. |
Mitchell AJ, Ferguson DW, Gill J, Paul J, Symonds P. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: A systematic review and meta-analysis. Lancet Oncol 2013;14:721-32. [PUBMED] |
26. |
Phelan SM, Griffin JM, Jackson GL, Zafar SY, Hellerstedt W, Stahre M, et al. Stigma, perceived blame, self-blame, and depressive symptoms in men with colorectal cancer. Psychooncology 2013;22:65-73. [PUBMED] |
27. |
Tsunoda A, Nakao K, Hiratsuka K, Yasuda N, Shibusawa M, Kusano M. Anxiety, depression and quality of life in colorectal cancer patients. Int J Clin Oncol 2005;10:411-7. [PUBMED] |
28. |
Earle CC, Chretien Y, Morris C, Ayanian JZ, Keating NL, Polgreen LA, et al. Employment among survivors of lung cancer and colorectal cancer. J Clin Oncol 2010;28:1700-5. [PUBMED] |
29. |
El-Shami K, Oeffinger KC, Erb NL, Willis A, Bretsch JK, Pratt-Chapman ML, et al. American Cancer Society colorectal cancer survivorship care guidelines. CA Cancer J Clin 2015;65:428-55. [PUBMED] |
30. |
Baniasadi N, Moghtader E, Khajehkazemi R, Mohebbi E. Increasing trend in colorectal cancer incidence in the Southeast of Iran 2003-2013: A population based cancer registry study. Asian Pac J Cancer Prev 2015;16:5257-60. [PUBMED] |
31. |
Vardanjani HM, Heidari M, Hadipour M. Can we rely on GLOBOCAN and GBD cancer estimates? Case study of lung cancer incidence and mortality rates and trends in Iran. Asian Pac J Cancer Prev 2016;17:3265-9. [PUBMED] |
32. |
Fazeli MS, Adel MG, Lebaschi AH. Colorectal carcinoma: A retrospective, descriptive study of age, gender, subsite, stage, and differentiation in Iran from 1995 to 2001 as observed in Tehran University. Dis Colon Rectum 2007;50:990-5. [PUBMED] |
33. |
Fallah M, Kharazmi E. Correction for under-ascertainment in cancer cases in the very elderly (aged 75+): External reference method. Cancer Causes Control 2008;19:739-49. [PUBMED] |
34. | |
35. | |
36. |
Aryaie M, Roshandel G, Semnani S, Asadi-Lari M, Aarabi M, Vakili MA, et al. Predictors of colorectal cancer survival in Golestan, Iran: A population-based study. Epidemiol Health 2013;35:e2013004. [PUBMED] |
37. |